Free Trial
→ Warren Buffett Issues Cryptic Warning on U.S. Dollar (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:SCLX

Scilex 3/11/2024 Earnings Report

Scilex logo
$26.28 +0.92 (+3.63%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$26.00 -0.28 (-1.07%)
As of 09/12/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings HistoryForecast

Scilex EPS Results

Actual EPS
-$8.75
Consensus EPS
-$7.35
Beat/Miss
Missed by -$1.40
One Year Ago EPS
N/A

Scilex Revenue Results

Actual Revenue
$13.46 million
Expected Revenue
$11.43 million
Beat/Miss
Beat by +$2.03 million
YoY Revenue Growth
N/A

Scilex Announcement Details

Quarter
Date
3/11/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Scilex's next earnings date is estimated for Wednesday, November 12, 2025, based on past reporting schedules.

Conference Call Resources

Scilex Earnings Headlines

Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announce Approval from Denali's Shareholders of the Previously Announced Business Combination
September 4, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/09/04/3144605/0/en/semnur-pharmaceuticals-inc-semnur-a-majority-owned-subsidiary-of-scilex-holding-company-nasdaq-sclx-scilex-and-denali-capital-acquisition-corp-announce-approval-from-denali-s-share.html
Scilex Holding Company (Nasdaq: SCLX) Announces Its Majority-Owned Subsidiary, Semnur Pharmaceuticals, Inc. (“Semnur”), and Denali Capital Acquisition Corp. Have Entered ...
August 21, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/GlobeNewswire/34296596/scilex-holding-company-nasdaq-sclx-announces-its-majority-owned-subsidiary-semnur-pharmaceuticals-inc-semnur-and-denali-capital-acquisition-corp-have-entered-into-a-purchase-agreement-with-an-investor-for-a-20-million-private/
Why Trump’s “Smart Dollar” could rewrite the rules
MUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's latest plans for the dollar – and they're so bold that one central bank chair says we haven't seen anything like it in almost a century. Our Wall Street insider says it's the start of a once-in-a-lifetime investing opportunity, IF you act now.tc pixel
 |  Stansberry Research (Ad)
Scilex Subsidiary Semnur Pharma Eyes $20M Private Placement Deal: More Details Inside
August 21, 2025  |  msn.comhttps://www.msn.com/en-us/money/companies/scilex-subsidiary-semnur-pharma-eyes-20m-private-placement-deal-more-details-inside/ar-AA1KX6rH
Scilex Holding Company and Semnur Pharmaceuticals Announce $20 Million Private Placement for SP-102 Clinical Trial and Leadership Transition
August 21, 2025  |  quiverquant.comQ
Scilex Holding Company (Nasdaq: SCLX) Announces Its Majority-Owned Subsidiary, Semnur Pharmaceuticals, Inc. (“Semnur”), and Denali Capital Acquisition Corp. Have Entered into a Purchase Agreement with an Investor for a $20 Million Private Placement at $16.00 per share and Jaisim Shah, Scilex's CEO and President, Will be Dedicated to Semnur on a Full Time Basis to Rapidly Advance SP-102 to Regulato
August 21, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/08/21/3136968/0/en/scilex-holding-company-nasdaq-sclx-announces-its-majority-owned-subsidiary-semnur-pharmaceuticals-inc-semnur-and-denali-capital-acquisition-corp-have-entered-into-a-purchase-agreem.html
See More Scilex Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Scilex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scilex and other key companies, straight to your email.

About Scilex

Scilex (NASDAQ:SCLX) Holdings, Inc. (NASDAQ: SCLX) is a specialty pharmaceutical company focused on non-opioid treatments for chronic pain. The firm’s principal commercial product, ZTlido®, is a lidocaine topical system approved by the U.S. Food and Drug Administration for the management of post-herpetic neuralgia and certain peripheral neuropathic pain conditions. By leveraging a proprietary drug delivery platform, Scilex aims to improve patient comfort and safety compared to traditional oral analgesics.

In addition to marketing ZTlido® in the United States, Scilex is advancing other pain management assets through clinical development and regulatory pathways. The company’s pipeline includes additional topical and localized therapies designed to address a range of acute and chronic pain indications without the abuse potential associated with opioid medications. Scilex pursues both in-house research and selective licensing partnerships to broaden its offering.

Headquartered in San Diego, California, Scilex operates primarily in the U.S. market, where it works with healthcare providers, specialty pharmacies and distributors to ensure patient access to its products. The company’s management team brings experience in pharmaceutical development, regulatory affairs and commercial operations, supporting Scilex’s strategy of targeted growth within the pain therapeutics space.

View Scilex Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles